Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

SCOPE-seq Analysis of Intra-operative Labeling Specificity of 5-ALA for Glioblastoma

ABSTRACT: SCOPE-seq Analysis of Intra-operative Labeling Specificity of 5-ALA for Glioblastoma

PROVIDER: PRJNA903155 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR22334917_1.fastq.gz	Fastqsanger.gz
	SRR22334917_2.fastq.gz	Fastqsanger.gz
	SRR22334918_1.fastq.gz	Fastqsanger.gz
	SRR22334918_2.fastq.gz	Fastqsanger.gz
	SRR22334919_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

SCOPE-seq Analysis of Intra-operative Labeling Specificity of 5-ALA for Glioblastoma

Project description:Glioblastoma (GBM) is the most common and aggressive malignant primary brain tumor, and surgical resection is a key part of the standard-of-care. In fluorescence-guided surgery (FGS), fluorophores are used to differentiate tumor tissue from surrounding normal brain. The heme synthesis pathway converts 5-aminolevulinic acid (5-ALA), a fluorogenic substrate, to the fluorophore protoporphyrin IX (PpIX). The resulting fluorescence is thought to be specific to transformed glioma cells, but this specificity has not been examined at single cell level. Here, we performed paired single cell imaging and RNA sequencing of individual cells (SCOPE-seq2) on human GBM surgical specimens with visible PpIX fluorescence from patients who received 5-ALA prior to surgery. SCOPE-seq2 allows us to simultaneously measure PpIX fluorescence by imaging and unambiguously identify transformed glioma cells from single-cell RNA-seq (scRNA-seq). We observed that 5-ALA treatment results in labeling that is not specific to transformed tumor cells. In cell culture experiments, we further demonstrated untransformed cells can be labeled by 5-ALA directly or by PpIX secreted from surrounding transformed cells. In acute slice cultures from mouse glioma models, we showed that 5-ALA preferably labels GBM tumor tissue over non-neoplastic brain tissue at bulk level, and that this contrast is not due to blood-brain-barrier disruption. Taken together, our findings support the use of 5-ALA as an indicator of GBM tissue, but not as a specific marker of transformed glioma cells.

2022-11-30 | GSE218331 | GEO

MESO-SCOPE, SCOPE cruise July 2017

Project description:MESO-SCOPE, SCOPE cruise July 2017 Raw sequence reads

| PRJNA981211 | ENA

Aspiration-assisted intra-operative 3D bioprinting of scaffold-free modular units for skeletal muscle tissue regeneration

Project description:Traumatic muscle injury associated with volumetric muscle loss results in reversible muscle regeneration and function. Bottlenecks to conventional tissue engineering strategies to augment muscle regeneration are limited by low cell transplantation capacity by conventional injection of dissociated cells, the lack of customization of engineered tissues based on muscle defect geometry, as well as the feasibility of intra-operative use. Here, we developed a facile approach to engineer modular units of scaffold-free high-density muscle tissues in customizable geometric shapes and sizes with integration potential. For the first time, we describe aspiration-assisted intra-operative bioprinting of scaffold-free modular units for preclinical treatment of volumetric muscle loss. We demonstrated the ability of 3D modular muscle units to be bioprinted to the site of the muscle defect, leading to improved muscle, vascular, and neuromuscular regeneration in a mouse model of volumetric muscle loss. Transcriptional profiling revealed that the scaffold-free muscle units enable pre-formed cell-cell interactions that support myogenesis, unlike dissociated cells that lack cell-cell interactions. This technology of intraoperative modular muscle unit implantation is promising for clinical use for precise bioprinting of scalable tissues from geometrically tunable modular units.

2025-05-31 | GSE292577 | GEO

Analysis of exonic somatic variants in light-chain amyloidosis (ALA) and ALA concomitant with multiple myeloma

Project description:We aim to provide the very first insight into ALA+MM molecular profiles and compare the results with ALA and with MM. Our detailed study of ALA and ALA+MM represents an important step towards improved understanding of their genetic and transcriptomic background, which is a prerequisite for development of optimal treatment strategies in the future.

| EGAS00001004214 | EGA

Seq-Scope analysis of human acne

Project description:Skin samples were analyzed through Seq-Scope.

2022-07-22 | GSE186601 | GEO

SCOPE FALKOR Eukaryotic Metatranscriptomes

Project description:SCOPE FALKOR Eukaryotic Metatranscriptomes Raw sequence reads

| PRJNA982163 | ENA

ALA-CPM

Project description:Interventions: 3-4 hours before the operation, 1.5 g (20 mg / kg) of araglio granules was dissolved in 50 ml of water and orally administered. Under general anesthesia and insufflation of carbon dioxide gas, the inside of the abdominal cavity is observed using a white and fluorescent light source device. The presence or absence of fluorescence is evaluated using normal light (white light) and blue light.;Oral administration of 5-ALA Primary outcome(s): ALA-PDD increases the accuracy of peritoneal metastasis (Comparison of sensitivity between white light and blue light) Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, diagnostic purpose

| 2614347 | ecrin-mdr-crc

5-ALA photodynamic metabolite-powered zero-waste “ferroptosis amplifier” for enhanced hypertrophic scar therapy

Project description:Hypertrophic scar (HS) is a somatopsychic disease that significantly affects quality of life. 5-aminolevulinic acid (5-ALA)-mediated photodynamic therapy (PDT) holds promise for HS treatment, while challenges like poor transdermal delivery and rapid metabolism into non_xfffe_photosensitive heme restrict its effectiveness. Inspired by the natural phenomenon of a whale fall nourishing life, this study innovatively repurposes 5-ALA metabolic waste, heme, as a “whale-like” energy source to drive ferroptosis, thus establishing a zero-waste therapy. This is achieved by encapsulating 5-ALA and baicalin within human H-ferritin (HFn), subsequently incorporated into polyvinylpyrrolidone (PVP) microneedles (FAB@MN). The FAB@MN exhibits excellent targeting towards hypertrophic scar fibroblasts (HSFs) with pH-responsive programmed drug release. Upon application, 5-ALA is converted into PpIX to initiate PDT. Subsequently, baicalin is released, triggering ferroptosis while also synergizing with the ROS and heme accumulated during PDT to overstimulate the HO-1-heme metabolic axis. This activation releases Fe2+ and CO, further potentiating ferroptosis. Moreover, the enhanced ferroptotic response driven by FAB@MN induces mitophagy, leading to increased Fe²⁺ release from the mitochondria. Unlike conventional PDT only focuses on immediate effects, this approach uses 5-ALA photodynamic waste to fuel a sustained ferroptosis response post-PDT, offering new avenues for HS treatments.

2025-06-24 | GSE300586 | GEO

Seq-Scope analysis of human acne

Project description:Seq-Scope analysis of human acne

| PRJNA774786 | ENA

Precise and broad scope genome editing based on high-specificity Cas9 nickases

Project description:Precise and broad scope genome editing based on high-specificity Cas9 nickases

| PRJNA642789 | ENA